JP Morgan Chase
AVBP icon

JP Morgan Chase’s ArriVent BioPharma AVBP Stock Holding History

JP Morgan Chase’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.26M Sell
65,692
-187
-0.3% -$5.52K ﹤0.01% 4102
2026
Q1 		$1.38M Sell
65,879
-3,515
-5% -$79.4K ﹤0.01% 4378
2025
Q4 		$1.4M Buy
69,394
+55,403
+396% +$1.15M ﹤0.01% 4374
2025
Q3 		$258K Sell
13,991
-418
-3% -$8.21K ﹤0.01% 5378
2025
Q2 		$314K Sell
14,409
-1,920
-12% -$39.9K ﹤0.01% 5010
2025
Q1 		$302K Buy
16,329
+644
+4% +$15.8K ﹤0.01% 5066
2024
Q4 		$418K Buy
15,685
+3,240
+26% +$93K ﹤0.01% 5137
2024
Q3 		$292K Buy
12,445
+8,050
+183% +$183K ﹤0.01% 5220
2024
Q2 		$81.5K Sell
4,395
-8,161
-65% -$146K ﹤0.01% 5629
2024
Q1 		$224K Buy
+12,556
New +$253K ﹤0.01% 5289

Other funds holding AVBP

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $983M AUM 26.53% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase's AVBP Position: Q2 2026 in Review

JP Morgan Chase reduced its ArriVent BioPharma (AVBP) stake by 0.28% in Q2 2026, selling an estimated $5.52K and leaving 65,692 shares worth $2.26M. The position accounts for ﹤0.01% of the portfolio, ranked #4102.

JP Morgan Chase first reported a position in AVBP in Q1 2024 and has held it in 10 quarters since. 157 funds tracked by Wall St. Rank hold AVBP as of Q2 2026.

  • JP Morgan Chase held 65,692 shares of ArriVent BioPharma worth $2.26M as of Q2 2026.
  • JP Morgan Chase sold 187 ArriVent BioPharma shares in Q2 2026, an estimated $5.52K.
  • ArriVent BioPharma made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #4102 holding.
  • JP Morgan Chase first reported a position in ArriVent BioPharma in Q1 2024 and has held it in 10 quarters since.
  • 157 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.